Advertisement

CardioVascular and Interventional Radiology

, Volume 41, Issue 1, pp 104–111 | Cite as

Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response

  • F. H. Cornelis
  • A. Borgheresi
  • E. N. Petre
  • E. Santos
  • S. B. Solomon
  • K. Brown
Clinical Investigation

Abstract

Purpose

Dedicated tumor feeding vessel detection software (TFVDS) using cone beam CT has shown a higher sensitivity to detect tumor feeding vessels during hepatic arterial embolization (HAE) of hepatocellular carcinoma (HCC) compared to 2D imaging. Our primary hypothesis was that HCC tumors treated with HAE guided by a TFVDS would show more complete response (CR) than when treated with 2D imaging alone. Secondary analysis of the impact on X-ray exposure was performed.

Materials and Methods

Nineteen males and 8 females (median age: 69 year, 46–85) with 44 tumors (median size: 38 mm, 6–100) treated with selective HAE between January 2013 and December 2014 were included. Exclusion criteria were: extra-hepatic supply, >4 tumors, tumor size >10 cm, and adjunctive local therapy. Baseline patient and procedure characteristics were reviewed. Differences in CR per modified Response Evaluation Criteria in Solid Tumors were assessed by univariate and multivariate analyses for tumor size, number, location, particles size, and use of TFVDS.

Results

Median imaging follow-up was 20.1 months (2–33). Use of TFVDS (13 patients, 19 tumors) was the only factor predictive of CR (OR = 3.85 [CI95%: 1.09, 13.67], p = 0.04) on univariate analysis but not on multivariate analysis (OR = 3.26 [0.87, 12.23], p = 0.08). A higher rate of CR was observed for HAE using TFVDS guidance versus 2D imaging alone (68.4%, 13–19, vs. 36%, 9–25, p = 0.03). Median dose area product was lower when TFVDS was used (149.7 Gy.cm2, 38–365, vs. 227.8 Gy.cm2, 85.3–468.6, p = 0.05).

Conclusions

HCC embolized with TFVDS may result in improved local tumor response without increasing the dose exposure.

Keywords

Hepatic arterial embolization Cone beam computed tomography Automated vessel tracking Tumor response 

Notes

Acknowledgements

The authors thank Gregoire Avignon, Clinical Research Engineer at GE Healthcare, for his technical support.

Funding

This study was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was waived for all individual participants included in the study.

References

  1. 1.
    Mauri G, Varano GM, Orsi F. TAE for HCC: when the old way is better than the new ones!!! Cardiovasc Intervent Radiol. 2016;39(6):799–800.CrossRefPubMedGoogle Scholar
  2. 2.
    Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33(3):552–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Bonomo G, Della Vigna P, Monfardini L, et al. Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session. Cardiovasc Intervent Radiol. 2012;35(6):1372–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Racadio JM, Babic D, Homan R, et al. Live 3D guidance in the interventional radiology suite. AJR Am J Roentgenol. 2007;189(6):W357–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Iwazawa J, Ohue S, Hashimoto N, Muramoto O, Mitani T. Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma. Eur J Radiol. 2012;81(12):3985–92.CrossRefPubMedGoogle Scholar
  6. 6.
    Ronot M, Abdel-Rehim M, Hakime A, et al. Cone-beam CT angiography for determination of tumor-feeding vessels during chemoembolization of liver tumors: comparison of conventional and dedicated-software analysis. J Vasc Interv Radiol. 2016;27(1):32–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: cone-beam CT during transarterial chemoembolization for liver cancer. Radiology. 2015;274(2):320–34.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pellerin O, Lin M, Bhagat N, Shao W, Geschwind JF. Can C-arm cone-beam CT detect a micro-embolic effect after TheraSphere radioembolization of neuroendocrine and carcinoid liver metastasis? Cancer Biother Radiopharm. 2013;28(6):459–65.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bapst B, Lagadec M, Breguet R, Vilgrain V, Ronot M. Cone beam computed tomography (CBCT) in the field of interventional oncology of the liver. Cardiovasc Intervent Radiol. 2016;39(1):8–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Deschamps F, Solomon SB, Thornton RH, et al. Computed analysis of three-dimensional cone-beam computed tomography angiography for determination of tumor-feeding vessels during chemoembolization of liver tumor: a pilot study. Cardiovasc Intervent Radiol. 2010;33(6):1235–42.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Iwazawa J, Ohue S, Hashimoto N, Mitani T. Comparison of the number of image acquisitions and procedural time required for transarterial chemoembolization of hepatocellular carcinoma with and without tumor-feeder detection software. Radiol Res Pract. 2013;2013:580839.PubMedPubMedCentralGoogle Scholar
  12. 12.
    European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer (Oxford, England: 1990). 2012;48(5):599–641.Google Scholar
  13. 13.
    Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(17):2046–53.CrossRefGoogle Scholar
  14. 14.
    Facciorusso A, Bellanti F, Villani R, et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United Eur Gastroenterol J. 2017;5(4):511–8.CrossRefGoogle Scholar
  15. 15.
    Massarweh NN, Davila JA, El-Serag HB, et al. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res. 2016;200(2):552–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang X, Erinjeri JP, Jia X, et al. Pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of liver tumors predicts subsequent treatment response. Cardiovasc Intervent Radiol. 2013;36(4):1030–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Jung E, Kim J, Yoon E, et al. The optimal tumor response assessment in patients with HCC after treatment of TACE. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4_suppl):215.CrossRefGoogle Scholar
  18. 18.
    Kothary N, Takehana C, Mueller K, et al. watershed hepatocellular carcinomas: the risk of incomplete response following transhepatic arterial chemoembolization. J Vasc Interv Radiol. 2015;26(8):1122–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS ONE. 2015;10(7):e0133488.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Basile A, Carrafiello G, Ierardi A, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765–74.CrossRefPubMedGoogle Scholar
  21. 21.
    Miyayama S, Yamashiro M, Hashimoto M, et al. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2013;24(4):501–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Minami Y, Yagyu Y, Murakami T, Kudo M. Tracking navigation imaging of transcatheter arterial chemoembolization for hepatocellular carcinoma using three-dimensional cone-beam CT angiography. Liver Cancer. 2014;3(1):53–61.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017

Authors and Affiliations

  • F. H. Cornelis
    • 1
    • 2
  • A. Borgheresi
    • 1
  • E. N. Petre
    • 1
  • E. Santos
    • 1
  • S. B. Solomon
    • 1
  • K. Brown
    • 1
  1. 1.Department of Radiology, Interventional Radiology ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of RadiologyTenon HospitalParisFrance

Personalised recommendations